DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies
In Brief: NCI Awards 4 Contracts For Enrichment Program; Dana-Farber Names Breast Center Leadership
NIH Authorization Set For Another Try; Women’s Cancers Are Targeted
DCT Advisers Ok Expansion of Phase 1, Phase 2 Testing
More DCT Concepts Approved By Advisors
Taxotere Encouraging, CPT-11, Other Agents Entering Trials; Chabner
Procedures For Ending IGs Announced
Trending Stories
- “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital
In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process - Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- How City of Hope is turning microbiome science into better cancer care









